Bone-targeted calcium phosphate-polymer hybrid nanoparticle co-deliver zoledronate and docetaxel to treat bone metastasis of prostate cancer.

Prostate cancer is the most common malignant tumor with bone metastasis, and there is still no ideal treatment for bone metastasis of prostate cancer. In this study, a pH and GSH dual sensitive calcium phosphate-polymer hybrid nanoparticle (DTX@Cap/HP) was prepared to co-deliver zoledronate (ZOL) and docetaxel (DTX) to treat bone metastasis of prostate cancer. DTX@Cap/HP exhibited high bone binding affinity and released more DTX and ZOL in acidic and high GSH concentration environment. A large amount of DTX@Cap/HP was uptaken by PC-3 cell in acidic medium than that in neutral medium. DTX@Cap/HP obviously reduced PC-3 cell proliferation and bone lesion in in-vitro 3D model of bone metastases of prostate cancer. Besides, DTX@Cap/HP also exhibited stronger anti bone metastases of prostate cancer activity in vivo as compared with the same dose of DTX+ZOL, which resulted from the co-delivery of DTX and ZOL to bone metastases of prostate cancer by DTX@Cap/HP and the synergistic effects of DTX and ZOL. DTX@Cap/HP has great potential in the treatment of bone metastases of prostate cancer.

Journal of pharmaceutical sciences. 2020 Nov 06 [Epub ahead of print]

Qian Yang, Dao-Zhou Liu, Miao Liu, Qi-Feng Ji, Qi-Bing Mei, Ying Cheng, Si-Yuan Zhou

Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an, 710032, China; Department of pharmacy, School of Medicine, Shaanxi Energy Institute, Xianyang, 712000, China., Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an, 710032, China., Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an, 710032, China. Electronic address: ., Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an, 710032, China. Electronic address: .